2022 Hires Reflect Global Challenges And Opportunities
A Tumultuous Year That Saw Senior Appointments At Teva, Fresenius, Stada And More
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.
You may also be interested in...
The start of 2023 has seen a number of firms across the off-patent industry announce management changes, with multiple appointments at Sandoz, a new CFO at Stada, a fresh CSO at Mallinckrodt, new generics leadership at Orion and board changes at Viatris and EuroAPI.
Teva has all but two US states on board for its long-hoped-for nationwide settlement to resolve opioid-related claims against the firm.
Biocon has seen its insulin-R application knocked back by the US FDA, with a complete response letter citing a need for more data as well as the need for remediation activities at its Bangalore facilities.